Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development

Keyphrases

• Hepatitis B Virus 100%
• Reverse Transcriptase 100%
• Drug Development 100%
• Antiretroviral Therapy 100%
• Protein Priming 40%
• Viral DNA Synthesis 30%
• Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) 30%
• Viral 20%
• DNA Synthesis 20%
• Chronic Hepatitis B Virus Infection 20%
• DNA Elongation 20%
• Antiviral Drugs 20%
• Host Factors 10%
• Interferon-α (IFN-α) 10%
• Mechanism of Action 10%
• Protein-DNA Complex 10%
• Pregenomic RNA (pgRNA) 10%
• Australia 10%
• Hepatitis B Virus Replication 10%
• Hepatitis B Virus Infection 10%
• Nucleoside Analogues 10%
• Proviral DNA 10%
• Viral Polymerase 10%
• Reverse Transcriptase Inhibitors 10%
• Non-competitive 10%
• Effective Compounds 10%
• Hepatitis B 10%
• Chemical Classes 10%
• Curative Treatment 10%
• Novel Protein 10%
• Hepatitis B Virus DNA 10%
• Nucleoside Reverse Transcriptase Inhibitors 10%
• Thymidine Analogs 10%
• Tenofovir 10%
• Viral Factors 10%
• Anti-hepatitis B Virus 10%
• Specific Recognition 10%
• Viral Inhibition 10%

Immunology and Microbiology

• Hepatitis B Virus 100%
• Reverse Transcriptase 100%
• DNA Synthesis 41%
• Hepatitis B 33%
• Viral Replication 16%
• interferon 8%
• Virus Nucleocapsid 8%
• Host Factor 8%
• DNA Virus 8%
• Hepatitis B Antigen 8%
• Virotherapy 8%
• Tenofovir 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Nonnucleoside Reverse Transcriptase Inhibitor 20%
• Entecavir 10%
• Clevudine 10%
• Tenofovir 10%